You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation*

Siu, Chung-Wah MBBS; Lau, Chu-Pak MD; Lee, Wai-Luen MBBS; Lam, Kwok-Fai PhD; Tse, Hung-Fat MD, PhD

Critical Care Medicine:
doi: 10.1097/CCM.0b013e3181a02f56
Continuing Medical Education Article
Abstract

Objectives: To compare the clinical efficacy of intravenous diltiazem, digoxin, and amiodarone for acute ventricular rate (VR) control in patients with acute symptomatic atrial fibrillation (AF) necessitating hospitalization.

Design: Randomized control trial.

Setting: Acute emergency medical admission unit in a regional teaching hospital in Hong Kong.

Patients: One hundred fifty adult patients with acute AF and rapid VR (>120 bpm).

Interventions: Patients were randomly assigned in 1:1:1 ratio to receive intravenous diltiazem, digoxin, or amiodarone for VR control.

Measurements and Main Results: The primary end point was sustained VR control (<90 bpm) within 24 hours; the secondary end points included AF symptom improvement and length of hospitalization. At 24 hours, VR control was achieved in 119 of 150 patients (79%). The time to VR control was significantly shorter among patients in the diltiazem group (log-rank test, p < 0.0001) with the percentage of patients who achieved VR control being higher in the diltiazem group (90%) than the digoxin group (74%) and the amiodarone group (74%). The median time to VR control was significantly shorter in the diltiazem group (3 hours, 1–21 hours) compared with the digoxin (6 hours, 3–15 hours, p < 0.001) and amiodarone groups (7 hours, 1–18 hours, p = 0.003). Furthermore, patients in the diltiazem group persistently had the lowest mean VR after the first hour of drug administration compared with the other two groups (p < 0.05). The diltiazem group had the largest reduction in AF symptom frequency score and severity score (p < 0.0001). In addition, length of hospital stay was significantly shorter in the diltiazem group (3.9 ± 1.6 days) compared with digoxin (4.7 ± 2.1 days, p = 0.023) and amiodarone groups (4.7 ± 2.2 days, p = 0.038).

Conclusions: As compared with digoxin and amiodarone, intravenous diltiazem was safe and effective in achieving VR control to improve symptoms and to reduce hospital stay in patients with acute AF.

Author Information

Assistant Professor (C-WS), Department of Medicine, the University of Hong Kong, Hong Kong, China; Honorary Clinical Professor (C-PL), Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong, China; Professor (W-LL), Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong, China; Associate Professor (K-FL), Department of Statistics and Actuarial Science, the University of Hong Kong, Hong Kong, China; and Professor (H-FT), Department of Medicine, the University of Hong Kong, Hong Kong, China.

For information regarding this article, E-mail: hftse@hkucc.hku.hk

The authors have not disclosed any potential conflicts of interest.

© 2009 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins